|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1994-11-10
|
|
pubmed:abstractText |
Thrombosis has been implicated as central to the clinical complications of coronary angioplasty (PTCA). Chimeric monoclonal 7E3 Fab (c7E3 Fab) is the first of a new class of antiplatelet drugs directed at the platelet glycoprotein IIb/IIIa integrin. This study was performed to determine the pharmacodynamics of c7E3 Fab administration during PTCA and to gain an initial clinical experience with this novel agent.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1757-64
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7923659-Angioplasty, Balloon, Coronary,
pubmed-meshheading:7923659-Antibodies, Monoclonal,
pubmed-meshheading:7923659-Dose-Response Relationship, Drug,
pubmed-meshheading:7923659-Female,
pubmed-meshheading:7923659-Hemorrhage,
pubmed-meshheading:7923659-Humans,
pubmed-meshheading:7923659-Immunoglobulin Fab Fragments,
pubmed-meshheading:7923659-Intraoperative Period,
pubmed-meshheading:7923659-Male,
pubmed-meshheading:7923659-Middle Aged,
pubmed-meshheading:7923659-Platelet Aggregation Inhibitors,
pubmed-meshheading:7923659-Preoperative Care,
pubmed-meshheading:7923659-Risk Factors,
pubmed-meshheading:7923659-Treatment Outcome
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
|
|
pubmed:affiliation |
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
